Clinical Research Directory
Browse clinical research sites, groups, and studies.
Dapagliflozin in Patients With Ulcerative Colitis
Sponsor: Mostafa Bahaa
Summary
The inflammatory bowel diseases (IBD) are described as complex, recurrent inflammatory conditions which are manifested as Crohn's disease (CD) and ulcerative colitis (UC). The common symptoms of IBD include debilitating/severe diarrhea, abdominal pain, weight loss, and chronic fatigue; events that may culminate in life-threatening complications. The pathogenesis of IBD has been characterized as complex/multi-factorial that includes disruption of intestinal epithelial barrier with consequent translocation of commensal microbial products as the prime event that instigates severe immune responses and intestinal inflammation.
Official title: Clinical Study to Evaluate Safety and Efficacy of Dapagliflozin in Patients With Ulcerative Colitis
Key Details
Gender
All
Age Range
18 Months - 60 Years
Study Type
INTERVENTIONAL
Enrollment
60
Start Date
2023-08-20
Completion Date
2026-08-20
Last Updated
2026-09-21
Healthy Volunteers
No
Conditions
Interventions
Mesalamine
Mesalamine, also known as 5-aminosalicylic acid (5-ASA), is a medication used to treat ulcerative colitis. It is usually used to induce or maintain remission of mildly to moderately active ulcerative colitis
Dapagliflozin 10mg Tab
Dapagliflozin has emerged as a selective SGLT2 inhibitor for the management of type-2 diabetes mellitus with minimal risk of hypoglycemia and it exerts diuretic-like actions and lowering of blood pressure, thereby, reducing the risk of hospitalization in type-2 diabetic patients with co-existing heart failure
Locations (1)
Faculty of Medicine, Mansoura University
Al Mansurah, Egypt